Metastasis-free survival as a surrogate endpoint in prostate cancer clinical trials

As many readers will have realized, the major regulatory authorities started, some time ago, to accept prostate cancer progression-free survival of differing types as a surrogate for overall survival in the approval of some drugs for the treatment of prostate cancer. … READ MORE …

Prostate cancer and treatment with immune checkpoint inhibitors

Immune checkpoint inhibitors include drugs like ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), and others that can have dramatic effects on the survival of some groups of patients with advanced forms of some cancers. … READ MORE …

An update on ODM-201 in the treatment of advanced prostate cancer

A while back now (in late 2014) Bayer initiated Phase III trials of the investigational agent ODM-201 — now also known as daralutamide — in the treatment of advanced prostate cancer. … READ MORE …

Anethole: might it be an effective prostate cancer drug?

We are well aware that many patients are interested in the potential of “natural products” as effective and safe forms of treatment for cancer. … READ MORE …

FDA accepts NDA for new formulation of abiraterone acetate

In  January and May this year we had noted that a company called Churchill Pharmaceuticals has been developing a different formulation of ultramicron-sized, oral abiraterone acetate (to be called Yonsa™). … READ MORE …

Can a “new Dendreon” re-make Provenge?

At the end of last week, Dendreon finally became a self-standing, wholly owned subsidiary of the Chinese company known as the Sanpower Group. … READ MORE …

This may be good news … or it may not …

Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …